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1 |  INTRODUCTION
A novel coronavirus strain (COVID-19) was identified as the 
cause of a severe acute respiratory distress syndrome (SARS-
CoV-2), which emerged in Wuhan, China in December 2019.1 
In the following months, the virus rapidly spread across the 
world, with a marked increase in cases occurring in the UK 
from March 2020. In response to this, the UK government 
enacted a lockdown which included the closure of schools 
and all non-essential business, effective from 23 March 2020 
(when just over 6000 cases were confirmed).2 The lockdown 
also included a directive to the population to ‘stay at home’ 
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Abstract
Aim: To describe the effect of the stringent lockdown measures, introduced in the UK 
on 23 March 2020 to curtail the transmission of COVID-19, on glycaemic control in 
people with type 1 diabetes using flash glucose monitoring.
Methods: We undertook an observational study of 572 individuals with type 1 diabetes 
for whom paired flash glucose monitoring data were available between early March 
and May 2020. The primary outcome was change in flash glucose monitoring vari-
ables. We also assessed clinical variables associated with change in glycaemic control.
Results: Percentage of time in range increased between March and May 2020 [median 
(interquartile range) 53 (41–64)% vs 56 (45–68)%; P < 0.001], with associated improve-
ments in standard deviation of glucose (P <0.001) and estimated HbA1c (P <0.001). 
There was a small reduction in the number of individuals meeting the hypoglycaemia 
target of <5% per day (64% vs 58%; P = 0.004). Comparing changes in flash glucose 
monitoring data from March to May in 2019 with the same period in 2020 confirmed that 
these differences were confined to 2020. Socio-economic deprivation was an independent 
predictor of a ≥5% reduction in time in range during lockdown (odds ratio 0.45 for people 
in the two most affluent Scottish Index of Multiple Deprivation quintiles; P <0.001).
Conclusions: Lockdown was not associated with a significant deterioration in glycae-
mic control in people with type 1 diabetes using flash glucose monitoring. However, 
socio-economic deprivation appeared to increase the risk of decline in glycaemic con-
trol, which has implications for how support is focused in challenging times.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
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with the exception of essential work, food/medicine shop-
ping and a single episode of daily exercise. Across the UK, 
diabetes services have generally cancelled all routine ‘face-
to-face’ outpatient activity during the COVID-19 crisis and, 
where possible, have delivered consultations ‘remotely’ by 
telephone and/or video calls.3 It is conceivable that the major 
upheaval in diet, physical activity, daily routine and stress 
associated with COVID-19, in addition to interruption in dia-
betes services, may have had a negative impact on glycae-
mic control in people with type 1 diabetes. To assess this, 
we interrogated our centre’s database to compare glycaemic 
variables in those with type 1 diabetes using flash glucose 
monitoring, both before and approximately 7 weeks after 
lockdown (whilst lockdown was still in place). In addition, 
we explored the clinical and demographic factors associated 
with decline in glycaemic control across this period.
2 |  PARTICIPANTS AND METHODS
2.1 | Study design and participants
Approximately 3340 individuals with type 1 diabetes attend 
Royal Infirmary of Edinburgh and Western General Hospital 
(Edinburgh) diabetes clinics. A total of 1776 individuals
(i.e. approximately half of all people with type 1 diabetes at-
tending our clinics) using flash glucose monitoring (FreeStyle 
Libre, Abbott, Witney, UK) have linked their glucose data to 
these clinics using the LibreView platform (libreview.com). Of 
1776 LibreView users, we identified a cohort with glucose data 
uploaded within 7 days of 11 March 2020 (baseline) and again 
within 7 days of 14 May 2020 (follow-up 7 weeks into lock-
down). Only individuals with ≥75% flash glucose monitoring 
data captured were included (n = 572). An additional analysis, 
comparing change in glycaemic variables between March to 
May 2019 and March to May 2020, was possible in 271/572 
people (i.e. paired data available for both 2019 and 2020).
2.2 | Outcomes
The main study outcomes were assessment of flash glucose 
monitoring glycaemic variables between March 2020 and 
May 2020 (using 2-week data capture), including average 
glucose, standard deviation of glucose, interquartile range of 
glucose, coefficient of variation glucose, number of low glu-
cose events per 2-week monitoring period, average low glu-
cose event duration, percentage of time spent with glucose 
below 3.9 mmol/l, percentage of time spent with glucose in 
range of 3.9–10 mmol/l, percentage of time spent with glu-
cose above 10 mmol/l, daily flash glucose monitoring scans, 
percentage of flash glucose monitoring data captured and 
estimated HbA1c. The percentage of individuals meeting the 
international consensus targets for time in range and time 
below range were also recorded.4 In addition to this, we com-
pared change across a range of glycaemic variables between 
March and May 2019 (non-lockdown control period) and 
March and May 2020 (lockdown period). Clinical and de-
mographic data including age, date of diabetes diagnosis, last 
clinic HbA1c value, method of insulin therapy (continuous 
subcutaneous insulin infusion or multiple daily injections), 
obesity (BMI > 30 kg/m2), smoking status and socio-eco-
nomic deprivation [Scottish Index of Multiple Deprivation 
(SIMD); simd.scot] were collected from SCI-Diabetes. SIMD 
data were unavailable in 24 individuals. We also sought to 
identify independent predictors (clinical and demographic) 
of decline in glycaemic control following lockdown.
2.3 | Statistical analysis
Data were mostly non-normally distributed (as determined by 
Shapiro–Wilk test) and are presented as median and interquar-
tile range (IQR). Paired data were analysed using the Wilcoxon 
signed-rank test and unpaired data using the Mann–Whitney 
U-test. Categorical data were analysed using the chi-squared 
or McNemar test, when comparing paired repeated measure-
ments. Logistic regression [odds ratios (ORs) and 95% CIs] was 
performed to identify independent predictors of deterioration in 
What's new?
• The COVID-19 pandemic is an unprecedented 
public health crisis and very little is known with 
respect to the effects of lockdown measures on 
glycaemic control.
• Interruption to standard diabetes services, stress 
and major upheaval to lifestyle and daily routines 
could all conceivably impact on glucose control in 
type 1 diabetes.
• We found no evidence of any clinically significant 
deterioration across a broad range of glycaemic 
variables in people with type 1 diabetes following 
the COVID-19 lockdown.
• If anything, some minor improvement was ob-
served in percentage time in target glucose range 
(3.9–10 mmol/l) between March 2020 (pre-lock-
down) and May 2020 (7 weeks into lockdown).
• Deterioration in time in range and estimated 
HbA1c during lockdown was more likely in people 
with higher levels of socio-economic deprivation.
• Even greater focus on support for people with type 
1 diabetes and socio-economic deprivation is im-
portant during the COVID-19 pandemic.
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continuous glucose monitoring variables. No sample size cal-
culation was performed. P values < 0.05 were taken to indicate 
statistical significance and no adjustment was made for multi-
plicity of statistical tests. All analyses were performed using 
RStudio version 1.0.153 (https://www.rstud io.com).
2.4 | Ethics
The study was entirely observational (with no deviation 
from standard clinical care) and ethics approval was not 
required. Inclusion in our national clinic database system, 
SCI-Diabetes (https://www.sci-diabe tes.scot.nhs.uk), in-
cludes permission to access data for audit purposes and in-
dividuals grant specific permission for clinic staff to access 
LibreView data when linking their devices to the clinic.
3 |  RESULTS
3.1 | Participant characteristics
The median (IQR) age of the cohort was 39 (31–50) years, 
and the median (IQR) diabetes duration was 18 (9–27) years. 
Of 572 participants, 301 (53%) were men and 147 (26%) 
were continuous subcutaneous insulin infusion users. A total 
of 336 participants out of 548 (61%) belonged to the two least 
deprived quintiles of SIMD (4 and 5), 143/569 participants 
(25%) were obese and 41/569 (7.2%) were current smokers. 
The median (IQR) last clinic-recorded HbA1c value was 60 
(53–67) mmol/mol [7.6 (7.0–8.3)%].
3.2 | Flash glucose monitoring variables 
between March and May 2020
There were statistically significant changes in all reported 
flash glucose monitoring variables, with the exception of co-
efficient of variation glucose, low glucose event duration and 
number of daily flash glucose monitoring scans (Table 1). 
The direction of all change in glycaemic variables following 
lockdown was broadly consistent with improved glycaemic 
control (Table 1 and Figure 1), although a small but statisti-
cally significant increase in low glucose events and percent-
age of time with glucose below 3.9 mmol/l was noted. A 
greater proportion of individuals met the time in range target 
and a smaller proportion met the hypoglycaemia target be-
tween March and May 2020 (Table 1).
3.3 | Comparison of 2019 and 2020
When comparing changes in flash glucose monitoring variables 
in the period March to May 2019 with the same period in 2020, 
T A B L E  1  Flash glucose monitoring data for the whole cohort in March and May 2020 (N = 572)
March 2020 May 2020
Median 
difference
P comparing March 
2020 and May 2020
Average glucose, mmol/l 9.6 (8.5 to 10.9) 9.3 (8.1 to 10.4) –0.4 (–1.1 to 0.3) <0.001
Sd glucose, mmol/l 3.6 (3.0 to 4.3) 3.5 (2.8 to 4.0) –0.2 (–0.5 to 0.2) <0.001
IQR glucose, mmol/l 5.0 (4.1 to 6.0) 4.8 (3.9 to 5.8) –0.2 (–0.8 to 0.4) <0.001
Coefficient of variation glucose, % 37 (33 to 42) 37 (33 to 42) –0.1 (–3.2 to 2.9) 0.420
Low glucose events, number/14 days 7 (3 to 12) 7 (3 to 14) 1 (–2 to 3) 0.003
Low glucose event duration, min 90 (60 to 120) 92 (65 to 127) 3 (–26 to 34) 0.061
% time below target range: <3.9 mmol/l 3 (1 to 6) 3 (1 to 7) 0 (–1 to 2) 0.005
% time in range: 3.9–10.0 mmol/l 53 (41 to 64) 56 (45 to 68) 3 (–4 to 10) <0.001
% time above range: >10.mmol/l 42 (29 to 56) 39 (25 to 51) –3 (–11 to 3) <0.001
Number of daily scans 10 (7 to 15) 10 (7 to 15) 0 (–2 to 1) 0.074
% flash glucose monitoring data captured 94 (90 to 97) 93 (88 to 96) –1 (–4 to 1) <0.001
Estimated HbA1c <0.001
mmol/mol 61 (53 to 69) 58 (50 to 66) –2 (–7 to 2)
% 7.7 (7.0 to 8.5) 7.5 (6.7 to 8.2) –0.2 (–0.6 to 0.2)
Time in range target met (>70%), n/N (%) 93/572 (16) 122/572 (21) NA 0.001
Hypoglycaemia target met (<5%), n/N (%) 365/572 (64) 332/572 (58) NA 0.004
Time in range and hypoglycaemia targets met, n/N (%) 55/572 (9.6) 65/572 (11) NA 0.261
Note Data are median (IQR), unless otherwise indicated.
Abbreviation: IQR, interquartile range.
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F I G U R E  1  Change in (a) estimated HbA1c, (b) percentage glucose below range, (c) percentage glucose in range and (d) percentage glucose 
above range between March 2020 and May 2020
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there were modest but significant improvements in percentage 
of time in range, estimated HbA1c and standard deviation in 
2020. There were statistically significant increases in low glu-
cose events and percentage of time below range (Table 2).
3.4 | Predictors of change in glycaemic 
variables during lockdown
Of 572 participants, 125 (22%) experienced a decrease in 
percentage of time in range of ≥5% during lockdown. The 
only statistically significant baseline associations in uni-
variate analysis were lower estimated HbA1c, greater time 
in range and greater socio-economic deprivation (Table 3). 
61/212 (28.8%) of those in the three most deprived quintiles 
(SIMD 1 - 3) experienced a decrease in percentage of time 
in range of ≥5%, compared to 60/336 (17.9%, P = 0.003) 
in the least deprived two quintiles (SIMD 4 & 5). Logistic 
regression analysis identified a lower risk in those belonging 
to the two SIMD quintiles with least deprivation [OR 0.45 
(95% CI 0.29–0.70); P < 0.001] and a greater risk for those 
with higher percentage of time in range at baseline [OR 1.03 
per % (95% CI 1.02–1.05); P < 0.001]. Socio-economic dep-
rivation was the only independent predictor of a ≥5-mmol/
mol (0.5%) increase in estimated HbA1c [which occurred in 
89/572 participants (16%)], with a lower risk observed in 
those belonging to the two quintiles with least deprivation 
[OR 0.41 (95% CI 0.25–0.67); P < 0.001 (Table 4)]. A ≥5% 
increase in percentage of time spent below 3.9 mmol/l was 
observed in 63/572 participants (11%) and the only inde-
pendent predictor was greater time in range at baseline [OR 
1.02 per % (95% CI 1.01–1.04); P = 0.008 Table 4)].
4 |  DISCUSSION
COVID-19 has resulted in an unprecedented public health 
emergency and extreme disruption to the lives of people 
across the world. Whilst there are a number of reasons to 
suspect that lockdown conditions could have a deleterious 
effect on glycaemic control in people with type 1 diabetes, 
this was not observed in a large cohort of individuals using 
flash glucose monitoring. In fact, these data suggest that, 
overall, there has been a small but significant improvement 
in important metrics such as time in range and estimated 
HbA1c. Although we have also shown statistically signif-
icant increases in low glucose metrics, these were negli-
gible and unlikely to be clinically relevant. Two recently 
reported smaller series have shown similar results, with no 
evident deterioration in glycaemic control during lockdown 
T A B L E  3  Comparison of clinical characteristics and how these related to subsequent change in time in range between March and May 2020 
(n = 572) in people in the Scottish Index of Multiple Deprivation quintiles 1 to 3 (most deprived) and those in quintiles 4 and 5 (least deprived)
TIR fell by ≥5% between March 
and May 2020 (n = 125)
TIR did not fall by ≥5% between 
March and May 2020 (n = 447) P
Age, years 38 (29–50) 39 (31–50) 0.735
Age at diagnosis, years 20 (13–31) 20 (11–29) 0.534
Diabetes duration, years 17 (9–25) 18 (10–28) 0.202
Men, n (%) 69 (55) 232 (52) 0.514
Women, n (%) 56 (45) 215 (48)
Baseline estimated HbA1c <0.001
mmol/mol 57 (50–62) 62 (53–70)
% 7.4 (6.7–7.8) 7.8 (7.0–8.6)
Baseline %TIR 59 (51–71) 51 (39–62) <0.001
Last clinic HbA1c value 0.361
mmol/mol 59 (52–67) 60 (53–68)
% 7.5 (6.9–8.3) 7.6 (7.0–8.4)
Continuous subcutaneous insulin infusion, n/N (%) 29/125 (23) 118/447 (26) 0.469
SIMD quintile categories (n = 548), n/N (%) 1–3: 61/121 (50)
4 and 5: 60/121 (50)
1–3: 151/427 (35)
4 and 5: 276/427 (65)
0.003
Obese, n/N (%) 29/124 (23) 114/445 (26) 0.613
Current smoker, n/N (%) 9/123 (7.3) 32/446 (7.2) 0.956
Note: Data are median (interquartile range). P compares those in whom TIR fell by ≥5% between March and May 2020 and those in whom this did not occur.
Abbreviations: SIMD, Scottish Index of Multiple Deprivation; TIR, time in range.
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in Italy and Spain.5,6 In fact, the Italian study showed that 
individuals who were not working during lockdown expe-
rienced improvements in key glucose metrics, consistent 
with the present findings.5 This suggests that standardiza-
tion of daily routine may have mediated some of the ben-
efits observed.
It is perhaps unsurprising that individuals with higher 
levels of time in range and lower estimated HbA1c are at 
greater risk of subsequent deterioration, as this may simply 
reflect regression to the mean. Of potentially greater inter-
est is the observation that higher levels of socio-economic 
deprivation were a strong, independent predictor of deteri-
orating glycaemic control during lockdown. The negative 
impact of socio-economic deprivation on glycaemic control 
is well recognized7 and there are several plausible explana-
tions as to why the COVID-19 crisis may have exacerbated 
this effect. For example, socio-economic deprivation may 
be disproportionately associated with poorer diet and re-
duced exercise during lockdown, as well as increased stress 
from childcare commitments and uncertainty around em-
ployment and income. Even greater challenges may exist for 
those not currently using modern glucose monitoring tech-
nologies and remote data-sharing. These individuals tend 
to have higher levels of socio-economic deprivation8 and 
may be at greater risk of deteriorating glycaemic control in 
the midst of this crisis. Emerging evidence also suggests 
that socio-economic deprivation and elevated HbA1c values 
are associated with adverse outcomes in individuals with 
COVID-19.9
A key strength of the present study is the cohort size, 
with the study representing the largest assessment of the 
effect of COVID-19 lockdown on glycaemic control in 
type 1 diabetes. An observational study is the only possi-
ble method of addressing this research question but raises 
the possibility that changes observed are not directly at-
tributable to lockdown. We sought to address this poten-
tial confounder by comparing changes across the same 
months (March to May) in both 2019 and 2020, with the 
former acting as a control. In doing so, we showed that 
our results are unlikely simply to represent seasonal vari-
ation in glycaemic control10 or incremental improvement 
in glycaemic control with longer duration of flash glucose 
monitoring. Another potential criticism of the study is that 
it is not generalizable to the wider type 1 diabetes popula-
tion. Flash glucose monitoring, even in the era of National 
Health Service funding, is skewed towards younger and 
more affluent individuals8 and continuous subcutaneous 
insulin infusion users were also over-represented in the 
present cohort. Our data were also limited to people with at 
least 75% data capture and therefore skewed towards more 
proactive flash glucose monitoring users. The reassuring 
findings from this study are likely to be generalizable to 
populations proactively using flash glucose monitoring, 
but not beyond this. This study was also limited to inter-
stitial glucose monitoring metrics and we cannot comment 
on the psychological impact and other person-centred out-
comes, which may be equally important to people with di-
abetes during this crisis. The large sample size identified 
statistically significant differences in several flash glucose 
monitoring variables, the magnitude of which would not be 
considered to be clinically meaningful.
In conclusion, these data provide reassurance that people 
with type 1 diabetes using flash glucose monitoring have not, 
in general, experienced significant deterioration in glycaemic 
control during the COVID-19 lockdown; however, the asso-
ciation between deteriorating control and socio-economic 
deprivation, even in those using flash glucose monitoring, 
is concerning. This has important implications for service 
TIR fell by ≥5% between 
March and May 2020
TBR increased by ≥5% 
between March and May 2020
OR 95% CI P OR 95% CI P
% in range at baseline 
(per % change)
1.01 1.00–1.02 0.189 1.02 1.01–1.04 0.008
Multiple daily 
injections
0.87 0.50–1.56 0.640 1.82 0.93–3.80 0.092
Age (per year) 1.00 0.98–1.02 0.896 1.00 0.98–1.03 0.959
Diabetes duration (per 
year)
0.99 0.97–1.01 0.357 1.02 1.00–1.04 0.120
Male 1.02 0.62–1.69 0.927 0.98 0.56–1.73 0.946
SIMD quintile 4 or 5 
(vs quintiles 1–3)
0.41 0.25–0.67 <0.001 1.20 0.68–2.18 0.530
Obese 0.88 0.49–1.54 0.670 0.94 0.47–1.75 0.844
Ever smoked 0.89 0.50–1.55 0.690 1.00 0.52–1.85 0.995
Abbreviations: SIMD, Scottish Index of Multiple Deprivation; TBR, time below range; TIR, time in range.
T A B L E  4  Logistic regression analysis 
of associations with reduction in time in 
range and increase in time below range 
between March and May 2020 (N = 539 
included in models)
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design to provide more effective support to those who require 
it most, particularly in challenging times.
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